Revenue, 2025

USD 232.32 Billion

Forecast, 2035

USD 599.3 Billion

CAGR, 2026-2035

9.94%

Report Coverage

Global

Contract Pharmaceutical Manufacturing Market Trends for 2026

The global contract pharmaceutical manufacturing market size was estimated at USD 232.32 billion in 2025 and is predicted to increase from USD 255.41 billion in 2026 to approximately USD 599.3 billion by 2035, expanding at a CAGR of 9.94% from 2026 to 2035.

The growing demand for biologics and specialty drugs is increasing the use of contract pharmaceutical manufacturing services. Additionally, growing innovations, generic product demand, technological advancement, new platform launches, and collaborations are also driving their use, enhancing the market growth.

Key Takeaways

• Contract pharmaceutical manufacturing market to crossed USD 255.41 billion by 2026.
• Market projected at USD 599.3 billion by 2035.
• CAGR of 9.94% expected in between 2026 to 2035.
• North America held the major revenue share of approximately 40% of the global contract pharmaceutical manufacturing market in 2025.
• Asia Pacific held the second-largest share of approximately 30% the market in 2025, and is expected to grow at a CAGR of 9.8% during the forecast period.
• By service type, the contract manufacturing (CMO) segment dominated the market with approximately 65% share in 2025.
• By service type, the contract research (CRO) segment held the second-largest share of approximately 35% in 2025, and is expected to grow at a notable CAGR during the forecast period.
• By product/service type, the finished dosage form (FDF) segment held a dominant revenue share of approximately 54% of the market in 2025.
• By product/service type, the API manufacturing segment held the second-largest share of approximately 46% of the market in 2025, and is expected to grow at a notable CAGR during the forecast period.
• By drug type, the small molecules segment held a dominant position in the contract pharmaceutical manufacturing market with a share of approximately 62% in 2025.
• By drug type, the biologics segment held the second-largest share of approximately 38% in 2025 and is expected to grow at a notable CAGR during the forecast period.
• By dosage form type, the oral segment registered its dominance over the global market with a share of approximately 60% in 2025.
• By dosage form type, the injectables segment held the second-largest share of approximately 30% of the market in 2025, and is expected to grow at a notable CAGR during the forecast period.

What is Contract Pharmaceutical Manufacturing?

The contract pharmaceutical manufacturing market is driven by the need for affordable services, shorter drug development timelines, and specialized expertise. Contract pharmaceutical manufacturing refers to the business agreement between the pharmaceutical companies and third-party organizations that help in the manufacturing of various pharmaceutical products. The companies outsource the drug products where these organization offers production, formulation, quality control, and packaging services.

Why is the Use of AI Increasing in the Contract Pharmaceutical Manufacturing Market?

The use of AI in contract pharmaceutical manufacturing is increasing, as it helps in the optimization of drug formulation by offering quality control and faster defect detection. It also offers process automation, which reduces manual errors and enhances batch consistency, documentation, and efficiency, which promotes regulatory compliance. Its predictive analysis reduces the chances of equipment failure and accelerates R&D activities, as well as supports clinical trials.

What are the Trends & Future Outlook of the Contract Pharmaceutical Manufacturing Market?

Blooming Advanced Therapies

The growing advancement in the biologics, personalized medicines, and biosimilars is increasing the demand for contract pharmaceutical manufacturing services, where they are also being utilized for the development of vaccines and targeted therapies.

Expanding Outsourcing Trends

The growth in the demand for advanced therapies, biologics, and other sterile products is driving the demand for contract pharmaceutical manufacturing services, leading to a rise in the outsourcing trends to accelerate their R&D, innovations, and commercialization.

Technological Advancements

The growing technological innovations are driving the adoption of new technologies to offer continuous manufacturing, as well as to enhance the manufacturing efficiency, speed, quality, and affordability, which is grabbing the attention of the pharmaceutical companies.

Executive Summary Table

Segmental Insights

By Service Type Insights

The Contract Manufacturing (CMO) Segment Dominated the Market in 2025

Explanation

• Contract Manufacturing (CMO) – Outsourced production of goods for companies, accounting for 65% share due to high demand for cost-effective manufacturing solutions.
• Contract Research (CRO) – Outsourced research and development services, holding 35% share with increasing reliance on external expertise for drug development and clinical trials.

The contract manufacturing (CMO) segment held the largest share of approximately 65% of the contract pharmaceutical manufacturing market in 2025, due to its affordable services and enhanced scalability. They focused on the R&D and innovation, which also attracted the consumers. The presence of specialized expertise and regulatory support also increased their use.

The contract research (CRO) segment held the second-largest share of approximately 35% of the market in 2025, driven by growing R&D complexities and rising cost pressure. Additionally, expanding clinical pipelines and clinical trials are also leading to their collaborations. Their expertise and advanced technologies are also attracting companies.

By Product/Service Insights

The Finished Dosage Form (FDF) Segment Dominated the Market in 2025

Explanation

• Finished Dosage Form (FDF) – The final form of pharmaceutical products ready for consumer use, accounting for 54% share due to higher demand for ready-to-use medications.
• API Manufacturing – Production of active pharmaceutical ingredients, holding 46% share with significant demand for raw materials used in drug formulations.

The finished dosage form (FDF) segment held the dominating share of approximately 54% of the contract pharmaceutical manufacturing market in 2025, due to growth in its production volume and formulation complexities. The rise in the demand for regulatory experts and faster product launches also increased the use of contract pharmaceutical manufacturing facilities. Additionally, growth in the outsourcing of generic products also increased their use.

The API manufacturing segment held the second-largest share of approximately 46% of the market in 2025, due to a surge in the generic pharmaceuticals. The growing interest in the development of new high-potency APIs is also increasing the use of contract pharmaceutical manufacturing services. The growing government support and outsourcing trends are also increasing their demand.

By Drug Type Insights

The Small Molecules Segment Dominated the Market in 2025

Explanation

• Small Molecules – Traditional pharmaceutical drugs, accounting for 62% share due to their widespread use and established manufacturing processes.
• Biologics – Complex, large-molecule drugs, holding 38% share with growing adoption for treating chronic and specialized conditions.

The small molecules segment held the largest revenue share of approximately 62% of the contract pharmaceutical manufacturing market in 2025, driven by the presence of oral formulations, which increase their acceptance rates, leading to a rise in their production volume. The growth in the demand for their generic version also propelled the reliance on the contract pharmaceutical manufacturing services. Their faster approval also increased the use of these services, which contributed to their innovations.

The biologics segment held the second-largest share of approximately 38% of the market in 2025, due to growing demand for targeted therapies, increasing chronic disease burden, and complex manufacturing process. The rise in the biologics pipeline and their faster approvals are also driving their innovations. Thus, all these factors are increasing the use of contract pharmaceutical manufacturing facilities.

By Dosage Form Insights

The Oral Segment Dominated the Market in 2025

Explanation

• Oral (Solid & Liquid) – Pills, tablets, and liquid medications, accounting for 60% share due to their convenience and widespread use.
• Injectables – Medications delivered via injection, holding 30% share with growing demand in specialty treatments and chronic disease management.
• Others (Topical, Inhalation, etc.) – Alternative dosage forms like creams and inhalers, representing 10% share with niche applications in specific therapeutic areas.

The oral segment held the major revenue share of approximately 60% of the contract pharmaceutical manufacturing market in 2025, driven by high patient acceptance rates and growth in its product volume. Their widespread applications and high demand for generic products also increased the use of contract pharmaceutical manufacturing for its affordable services. Additionally, their advanced technologies and standard processes also led to new collaborations.

The injectables segment held the second-largest share of approximately 30% of the market in 2025, due to growth in the biologics. Their enhanced efficacy, bioavailability, and rapid action also increase their acceptance rates. The growing advancements in vaccines and monoclonal antibodies are also increasing their use, which in turn is promoting the use of contract pharmaceutical manufacturing facilities.

Regional Insights

Robust Industries Drives North America

North America dominated the contract pharmaceutical manufacturing market with approximate 40% in 2025, due to the rise of robust pharmaceutical industries, which increased the outsourcing trends driving the adoption of contract pharmaceutical manufacturing services. The growth in the R&D activities and investments also increased their use, where the technological advancement also contributed to their increased use and market growth.

U.S. Market Trends

The presence of top pharma and biotech companies in the U.S. is increasing the use of CMO and CDMO services due to growing outsourcing trends. The growing R&D investments and increasing advancement in APIs, sterile products, and biologics are also increasing their demand. Additionally, advanced technologies and regulatory expertise are also attracting the companies.

Large Manufacturing Base Boosts Asia Pacific

Asia Pacific held the second-largest share of approximately 30% of the contract pharmaceutical manufacturing market in 2025 and is expected to grow with a significant CAGR of 9.8% during 2026-2035 due to the presence of a large manufacturing base, where the growing demand for generics and biologics is also increasing the collaboration with CMOs & CDMOs. The growing diseases and government support are also increasing the use of contract pharmaceutical manufacturing services, enhancing the market growth.

India Market Trends

The growing adoption of generic products and biosimilars in India is increasing the collaboration with the contract pharmaceutical manufacturing facilities. The presence of a large manufacturing base and its affordable services are also increasing its use. The growing government initiatives and increasing outsourcing trends are also increasing their partnerships.

Europe Driven by Stringent Regulatory Framework

Europe is expected to grow significantly in the contract pharmaceutical manufacturing market due to a robust regulatory framework, which increases the demand for high-quality manufacturing, driving collaborations with the contract pharmaceutical manufacturing facilities. The presence of advanced pharmaceutical companies and growing demand for biologics are also increasing their use, promoting the market growth.

UK Market Trends

The UK consists of robust pharmaceutical and biotechnology industries, which are increasing the use of contract pharmaceutical manufacturing services due to a rise in the development of small molecules and biologics. The advanced manufacturing infrastructure, skilled personnel, and regulatory expertise are also attracting the companies.

Contract Pharmaceutical Manufacturing Market Value Chain Analysis

R&D

• The R&D of the contract pharmaceutical manufacturing focuses on the development of advanced drug delivery systems, cell and gene therapy platforms, and AI-driven process optimization.
• Key players: Lonza Group, Catalent, Inc., WuXi AppTec.

Clinical Trials and Regulatory Approvals

• The manufacturing consistency, safety, and efficacy are evaluated in the clinical trials and regulatory approvals of the contract pharmaceutical manufacturing.
• Key players: Samsung Biologics, Thermo Fisher Scientific (Patheon), Lonza Group.

Formulation and Final Dosage Preparation

• The formulation and final dosage preparation of the contract pharmaceutical manufacturing focuses on optimization of drug stability, delivery formats, and solubility.
• Key players: Recipharm AB, Catalent, Inc., Thermo Fisher Scientific (Patheon).

Packaging and Serialization

• The packaging and serialization of the contract pharmaceutical manufacturing involves the use of secure primary and secondary containers, tamper-evident labelling, and unique track-and-trace coding.
• Key players: Catalent, Inc., Thermo Fisher Scientific (Patheon), Akums Drugs & Pharmaceuticals.

Distribution to Hospitals, Pharmacies

• The cold-chain logistics, last-mile delivery, and secure wholesale supply chains are responsible for the distribution of contract-manufactured pharmaceuticals to the hospitals and pharmacies.
• Key players: McKesson, Cardinal Health, and AmerisourceBergen.

Patient Support and Services

• The reimbursement assistance, specialized home-delivery, and adherence programs are provided in the patient support and services by the contract pharmaceutical manufacturing facilities.
• Key players: McKesson, Cardinal Health, and AmerisourceBergen.

Who are the Contract Pharmaceutical Manufacturing Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The contract pharmaceutical manufacturing services offer affordable services which attracting the consumers.
• Their enhanced scalability and presence of expertise are also increasing their acceptance rates.
• They also help in faster drug development and commercialization, which promotes their use.
• Additionally, advanced technologies and regulatory experts are also increasing their use.

Weaknesses

• The dependence on the clients acts as the major weakness in the contract pharmaceutical manufacturing market, which limits their growth.
• The limited control of the pharmaceutical companies over the product manufacturing process also limits their use.

Opportunities

• The growing demand for generic products and biologics is increasing the use of contract pharmaceutical manufacturing services.
• The growing advancements in complex therapies have also increased their demand.
• The rise in outsourcing treatments is also leading to the growth in collaborations among companies.
• Moreover, growing adoption of advanced technologies is also attracting companies.

Threats

• The growth in the in-house manufacturing facilities is decreasing the use of contract pharmaceutical manufacturing facilities.
• The growing market competition and regulatory complexities also limit their use.

Recent Developments in the Contract Pharmaceutical Manufacturing Market

• In March 2026, a strategic collaboration between Suzhou Langrui Biopharmaceutical Co., Ltd. (LexBio) and Wuhan Hiteck Biopharmaceutical Co., Ltd. was announced, where they will integrate preclinical development and commercial manufacturing capabilities of Hiteck with LexBio's 1.2 billion-compound AI-powered discovery platform to enhance the small-molecule therapies for the treatment of inflammatory diseases.
• In March 2026, to support the pharmaceutical, diagnostics, and biotechnology organizations across the U.S., Canada, and Europe, and other markets by providing contract research organization ("CRO") services for custom aptamer discovery, machine-learning ("ML") classification, and biosensor enablement, was announced by the wholly-owned subsidiary, Triera Biosciences Ltd. of Zentek.

Segments Covered in the Report

By Service Type

• Contract Manufacturing (CMO)
• Contract Research (CRO)

By Product/Service

• Finished Dosage Form (FDF)
• API Manufacturing

By Drug Type

• Small Molecules
• Biologics

By Dosage Form

• Oral (Solid & Liquid)
• Injectables
• Others (Topical, Inhalation, etc.)

By Workflow

• Commercial Manufacturing
• Clinical Manufacturing

By End User

• Large Pharmaceutical Companies
• Small & Mid-size Pharma/Biotech    
• Generic Companies & Others

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA